A052260 Stock Overview
Engages in the manufacture and sale of natural materials for cosmetics, nutraceuticals, and regenerative medicines worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
HYUNDAI BIOLAND Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,810.00 |
| 52 Week High | ₩7,900.00 |
| 52 Week Low | ₩4,215.00 |
| Beta | 0.43 |
| 11 Month Change | 27.97% |
| 3 Month Change | -4.44% |
| 1 Year Change | 8.50% |
| 33 Year Change | -42.04% |
| 5 Year Change | -6.67% |
| Change since IPO | 232.00% |
Recent News & Updates
Optimistic Investors Push HYUNDAI BIOLAND Co.,Ltd. (KOSDAQ:052260) Shares Up 27% But Growth Is Lacking
Aug 11
Some Investors May Be Worried About HYUNDAI BIOLANDLtd's (KOSDAQ:052260) Returns On Capital
Jul 26Is HYUNDAI BIOLANDLtd (KOSDAQ:052260) A Risky Investment?
May 25Recent updates
Optimistic Investors Push HYUNDAI BIOLAND Co.,Ltd. (KOSDAQ:052260) Shares Up 27% But Growth Is Lacking
Aug 11Some Investors May Be Worried About HYUNDAI BIOLANDLtd's (KOSDAQ:052260) Returns On Capital
Jul 26Is HYUNDAI BIOLANDLtd (KOSDAQ:052260) A Risky Investment?
May 25Subdued Growth No Barrier To HYUNDAI BIOLAND Co.,Ltd. (KOSDAQ:052260) With Shares Advancing 28%
May 03Impressive Earnings May Not Tell The Whole Story For HYUNDAI BIOLANDLtd (KOSDAQ:052260)
Mar 19Should You Buy HYUNDAI BIOLAND Co.,Ltd (KOSDAQ:052260) For Its Dividend?
Apr 12HYUNDAI BIOLAND Co.,Ltd's (KOSDAQ:052260) Financial Prospects Don't Look Very Positive: Could It Mean A Stock Price Drop In The Future?
Mar 08Update: HYUNDAI BIOLANDLtd (KOSDAQ:052260) Stock Gained 14% In The Last Five Years
Feb 15The Returns At HYUNDAI BIOLANDLtd (KOSDAQ:052260) Provide Us With Signs Of What's To Come
Jan 28Tread With Caution Around HYUNDAI BIOLAND Co.,Ltd's (KOSDAQ:052260) 1.5% Dividend Yield
Jan 10HYUNDAI BIOLANDLtd (KOSDAQ:052260) Takes On Some Risk With Its Use Of Debt
Dec 23Are Poor Financial Prospects Dragging Down HYUNDAI BIOLAND Co.,Ltd (KOSDAQ:052260 Stock?
Dec 05
The HYUNDAI BIOLANDLtd (KOSDAQ:052260) Share Price Is Up 55% And Shareholders Are Holding On
Nov 17Shareholder Returns
| A052260 | KR Personal Products | KR Market | |
|---|---|---|---|
| 7D | 3.6% | 1.6% | 1.9% |
| 1Y | 8.5% | -4.3% | 5.0% |
Return vs Industry: A052260 exceeded the KR Personal Products industry which returned -4.3% over the past year.
Return vs Market: A052260 exceeded the KR Market which returned 5% over the past year.
Price Volatility
| A052260 volatility | |
|---|---|
| A052260 Average Weekly Movement | 8.9% |
| Personal Products Industry Average Movement | 8.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A052260 has not had significant price volatility in the past 3 months.
Volatility Over Time: A052260's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 320 | Chan-Bok Jeong | www.hyundaibioland.co.kr |
HYUNDAI BIOLAND Co.,Ltd. engages in the manufacture and sale of natural materials for cosmetics, nutraceuticals, and regenerative medicines worldwide. The company’s cosmetics includes whitening, skin protection, moisturizing, anti-aging, sheet mask, and hair and body care products; and functional food ingredients comprising various nutraceuticals and general food raw ingredients.
HYUNDAI BIOLAND Co.,Ltd. Fundamentals Summary
| A052260 fundamental statistics | |
|---|---|
| Market cap | ₩174.30b |
| Earnings (TTM) | ₩7.92b |
| Revenue (TTM) | ₩105.48b |
22.0x
P/E Ratio1.7x
P/S RatioIs A052260 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A052260 income statement (TTM) | |
|---|---|
| Revenue | ₩105.48b |
| Cost of Revenue | ₩66.77b |
| Gross Profit | ₩38.72b |
| Other Expenses | ₩30.79b |
| Earnings | ₩7.92b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 264.15 |
| Gross Margin | 36.70% |
| Net Profit Margin | 7.51% |
| Debt/Equity Ratio | 23.7% |
How did A052260 perform over the long term?
See historical performance and comparison